Dang Yuan, Wei Xudong, Xue Laien, Wen Fuli, Gu Jianjun, Zheng Heping
Clin Lab. 2018 Jun 1;64(6):887-894. doi: 10.7754/Clin.Lab.2018.180107.
Glioma is one of the most common and aggressive malignant tumors of the central nervous system.
Here, we review and explore the use of long noncoding RNA (lncRNA) as a therapeutic strategy for the targeting of gliomas.
LncRNA is a functional RNA molecule with no protein coding function and is involved in the occurrence and progression of glioma. It is reported that the activation of several signaling pathways, including the MAPK, p53, Wnt/β-catenin, PI3K/AKT/mTOR, and epithelial mesenchymal transformation (EMT) pathways, are involved in the regulation of gliomas. In addition, microRNAs in glioma may also interact with lncRNAs and affect tumor growth and progression.
Therefore, the exploration of lncRNA participation in signaling pathway regulatory mechanisms and the determination of the interaction between lncRNA and miRNA may help to develop new effective therapies for the treatment of glioma.
胶质瘤是中枢神经系统最常见且侵袭性最强的恶性肿瘤之一。
在此,我们回顾并探讨将长链非编码RNA(lncRNA)用作靶向胶质瘤的治疗策略。
lncRNA是一种无蛋白质编码功能的功能性RNA分子,参与胶质瘤的发生和进展。据报道,包括丝裂原活化蛋白激酶(MAPK)、p53、Wnt/β-连环蛋白、磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)以及上皮-间质转化(EMT)途径在内的多种信号通路的激活均参与胶质瘤的调控。此外,胶质瘤中的微小RNA(miRNA)也可能与lncRNA相互作用并影响肿瘤生长和进展。
因此,探索lncRNA参与信号通路调控机制以及确定lncRNA与miRNA之间的相互作用可能有助于开发治疗胶质瘤的新型有效疗法。